Probiotics You Spray on Your Underwear? The Results
November 6, 2026Health Canada Seized 11,400 Vials of Bacteria-Laced Peptides
November 8, 2026Quick Summary
Researchers at the University of Surrey gave 61 healthy adults over 40 a daily 15-gram scoop of a 12-ingredient “longevity” powder — or an identical placebo — for six months. Blood vessel function improved within an hour of the very first dose, and after six months the supplement group had more flexible arteries and systolic blood pressure 6.1 points lower than the placebo group. The catch: only 43 of the 61 finished the trial, it measured markers rather than heart attacks, and the company behind the powder helped pay for it.
One hour. That is how long it took for a spoonful of powder to show up in people’s arteries. In a new trial published this week, healthy adults over 40 swallowed a daily “longevity” blend — and sixty minutes later, their blood vessels were already behaving differently from the placebo group’s. Six months on, the gap had grown into lower blood pressure and arteries that were measurably more flexible. It is the kind of result that makes a supplement sound like a shortcut — and the kind that deserves a careful look before anyone reaches for their wallet.
| Topic | What the research shows |
|---|---|
| The trial | STAMINA: 61 healthy non-smokers aged 40 and up, randomized, double-blind and placebo-controlled, run at the University of Surrey with Royal Surrey NHS Foundation Trust |
| The powder | One 15-gram scoop a day with 12 ingredients, including vitamin C, magnesium, glycine, fisetin, rhodiola and pterostilbene |
| Blood vessel function | Flow-mediated dilation improved 2.9 points more than placebo after 6 months — and was already 3.9 points ahead one hour after the first dose |
| Blood pressure | Systolic pressure fell 6.1 mmHg more than placebo after 6 months |
| Arterial stiffness | Pulse wave velocity was 1.18 m/s better than placebo |
| The fine print | Only 43 of 61 people finished the trial; the study tracked markers, not heart attacks; the powder’s maker helped fund it |
What the Trial Actually Found
The study, called STAMINA, is the first human trial of a whole “longevity” formula rather than a single ingredient. Sixty-one healthy, non-smoking adults aged 40 and older were split at random — 33 got the powder, 28 got a placebo matched for look and taste — and everyone took one 15-gram scoop a day in water or juice for six months. The trial was pre-registered (NCT06145087) and published in the European Heart Journal Open.
The main thing the researchers measured was flow-mediated dilation — a mouthful that boils down to a simple idea. An ultrasound watches the artery in your upper arm while a cuff squeezes it for five minutes, then lets go. A healthy artery widens as blood rushes back in — the more it widens, the better your blood vessels are working, which makes this a top early warning sign for researchers.
| Measure | Supplement group vs. placebo after 6 months |
|---|---|
| Blood vessel function (FMD) | Improved 2.9 percentage points more than placebo — about a 47% rise from where the group started |
| Arterial stiffness (PWV) | 1.18 m/s better than placebo; stiffness fell 0.78 m/s in the supplement group while rising 0.56 m/s on placebo |
| Systolic blood pressure | 6.1 mmHg lower than placebo |
| Cholesterol and triglycerides | No change in either group |
| Estimated 10-year heart risk | Down 0.45 percentage points vs. placebo, driven by the blood pressure change rather than lipids |
Those numbers are worth a moment of context. Arterial stiffness normally creeps up by roughly 1 metre per second every decade of adult life — so a 1.18 m/s gap is roughly a decade’s worth of stiffening, in either direction. And earlier large studies have linked a sustained 5-point drop in systolic pressure with roughly 10% fewer major cardiovascular events. That is context, not a promise: this trial measured no heart attacks or strokes.
Why the One-Hour Result Is the Real Story
The six-month numbers are impressive. The one-hour number is the one that makes researchers sit up. Flow-mediated dilation was already 3.9 percentage points ahead of placebo sixty minutes after the very first scoop. Arteries do not remodel themselves in an hour, so something faster is going on — a rapid change in how blood vessels behave, most likely through nitric oxide, the molecule that tells vessel walls to relax.
Study author Christian Heiss, the trial’s lead researcher at the University of Surrey, put it carefully: the rapid response suggests at least part of the effect reflects a quick change in vascular function rather than structural changes in the arteries. The six-month readings were taken about a day after the last dose, so the effect was still there well past the immediate post-dose window.
Here is the honest unknown: with 12 ingredients in the scoop, nobody can say which one did the work — or whether it was the combination. Several ingredients have individually been linked to nitric oxide and blood vessel pathways, but this study was not designed to untangle them. That matters, because you cannot buy the same result by picking up one or two of the ingredients on their own — the trial tested one specific formula, at specific doses, as a whole.
The idea behind the formula is genuinely interesting, though. Ageing does not run through a single pathway — it is a tangle of oxidative stress, low-grade inflammation, flagging mitochondria and more. The thinking is that hitting several of those pathways at once, with smaller doses of each ingredient, might do more than a large dose of any single one. Until now, almost nobody had tested that idea properly in people.
The Fine Print: Small, Leaky, and Company-Funded
Now the part that should cool any excitement. First, the trial was small — and it got smaller: 61 people were randomized, but only 43 completed both visits. Nearly one in three dropped out, and small trials with heavy dropout are exactly the kind that can flatter a result. The authors call their own findings preliminary.
Second, everything measured was a marker, not an outcome. Better flow-mediated dilation and lower pulse wave velocity are encouraging signs, but they are not heart attacks avoided or strokes prevented. The estimated 10-year risk score did fall, but that is a calculation built mostly from the blood pressure change — not a count of real events.
Third, the money. The supplement’s maker supplied the powder and the matching placebo and made an unrestricted contribution toward the research costs. The company says it had no role in the study design, data collection, or the decision to publish, and the university kept control of the data. That is the right setup — but one co-author is the company’s own director of research and development, and independent replication is still missing. Until another team, with other funding, finds the same thing, this stays an early signal.
Fourth, the volunteers were a narrow group: healthy, non-smoking, mostly with blood pressure already in the normal range. That makes the result harder to dismiss — change is toughest to show in people who are already doing well — but it also means we know nothing about how the formula behaves in people with high blood pressure, heart disease, or other health conditions. And it is no substitute for blood pressure treatment: nobody should swap a prescribed medication for a powder on the strength of a 61-person trial.
What This Means If You Shop for Supplements
Strip away the hype and there are two useful takeaways here. The first is about the idea, not the product: testing a whole formula in a proper randomized trial is a higher bar than most supplement claims ever clear, and the multi-pathway approach is a real question worth answering. The second is about the standard to hold “longevity” products to. Even the company’s own chief executive says the bar should be randomized, placebo-controlled human trials of the whole formula, run by independent researchers and published after peer review — and he encourages shoppers to ask that of every brand, including his own. Most products on the longevity shelf cannot meet it.
For now, the fair summary is this: a small, company-supported trial found that a 12-ingredient powder improved three markers of blood vessel health over six months, with the first change showing up within an hour. It is encouraging and preliminary, and it needs a bigger, longer, independent sequel before anyone treats it as settled. The blood vessels noticed something in an hour. Science will take a little longer.
References
- Piercy, C., et al. (2026). Acute and 6-month vascular effects of a multi-component nutritional supplement: A randomized controlled trial. European Heart Journal Open, 6(6), oeag157. https://doi.org/10.1093/ehjopen/oeag157
- Medical News Today. (2026, November 6). ‘Longevity’ supplement shows promise for vascular health biomarkers. https://www.medicalnewstoday.com/amp/articles/nutritional-supplement-may-improve-blood-vessel-health-markers-clinical-trial-suggests
- NutraIngredients. (2026, November 5). RCT supports NOVOS Core’s benefits for cardiovascular health in healthy adults. https://www.nutraingredients.com/Article/2026/11/05/rct-supports-novos-cores-benefits-for-cardiovascular-health-in-healthy-adults/
- ClinicalTrials.gov. (n.d.). Effects of a supplement to target ageing mechanisms on vascular function (STAMINA) — NCT06145087. https://clinicaltrials.gov/study/NCT06145087
This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.
